Literature DB >> 26616870

Berberine is a dopamine D1- and D2-like receptor antagonist and ameliorates experimentally induced colitis by suppressing innate and adaptive immune responses.

Masaaki Kawano1, Rie Takagi1, Atsushi Kaneko2, Sho Matsushita3.   

Abstract

Berberine is an herbal alkaloid with various biological activities, including anti-inflammatory and antidepressant effects. Here, we examined the effects of berberine on dopamine receptors and the ensuing anti-inflammatory responses. Berberine was found to be an antagonist at both dopamine D1- and D2-like receptors and ameliorates the development of experimentally induced colitis in mice. In lipopolysaccharide-stimulated immune cells, berberine treatment modified cytokine levels, consistent with the effects of the dopamine receptor specific antagonists SCH23390 and L750667. Our findings indicate that dopamine receptor antagonists suppress innate and adaptive immune responses, providing a foundation for their use in combatting inflammatory diseases.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antagonist; Autoimmune disease; Berberine; Dopamine receptors; Innate immune response; T helpers

Mesh:

Substances:

Year:  2015        PMID: 26616870     DOI: 10.1016/j.jneuroim.2015.10.001

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  19 in total

Review 1.  Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease.

Authors:  S M Matt; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2019-05-11       Impact factor: 4.147

2.  Cluster Analysis of Medicinal Plants and Targets Based on Multipartite Network.

Authors:  Namgil Lee; Hojin Yoo; Heejung Yang
Journal:  Biomolecules       Date:  2021-04-08

Review 3.  The impact of substance abuse on HIV-mediated neuropathogenesis in the current ART era.

Authors:  Vanessa Chilunda; Tina M Calderon; Pablo Martinez-Aguado; Joan W Berman
Journal:  Brain Res       Date:  2019-08-29       Impact factor: 3.252

4.  Therapeutic switching of sulpiride, an anti-psychotic and prokinetic drug, to an anti-colitic drug using colon-specific drug delivery.

Authors:  Dohoon Kim; Wooseong Kim; Seongkeun Jeong; Dayoon Kim; Jin-Wook Yoo; Yunjin Jung
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

Review 5.  Targeting the Dopaminergic System in Autoimmunity.

Authors:  Pia M Vidal; Rodrigo Pacheco
Journal:  J Neuroimmune Pharmacol       Date:  2019-01-19       Impact factor: 4.147

Review 6.  Recent Trends in Pharmacological Activity of Alkaloids in Animal Colitis: Potential Use for Inflammatory Bowel Disease.

Authors:  Ana Cristina Alves de Almeida; Felipe Meira de-Faria; Ricardo José Dunder; Luis Paulo Bognoni Manzo; Alba Regina Monteiro Souza-Brito; Anderson Luiz-Ferreira
Journal:  Evid Based Complement Alternat Med       Date:  2017-01-09       Impact factor: 2.629

7.  Berberine alleviates dextran sodium sulfate-induced colitis by improving intestinal barrier function and reducing inflammation and oxidative stress.

Authors:  Li-Chao Zhang; Yue Wang; Ling-Chang Tong; Sheng Sun; Wei-Ye Liu; Su Zhang; Rong-Mei Wang; Zhi-Bin Wang; Ling Li
Journal:  Exp Ther Med       Date:  2017-04-28       Impact factor: 2.447

8.  Potential Prophylactic Effect of Berberine against Rat Colon Carcinoma Induce by 1,2-Dimethyl Hydrazine

Authors:  Ahmed E Ghareeb; Fatma S M Moawed; Doaa A Ghareeb; Eman I Kandil
Journal:  Asian Pac J Cancer Prev       Date:  2018-06-25

9.  A colon-specific prodrug of metoclopramide ameliorates colitis in an experimental rat model.

Authors:  Yejin Yang; Wooseong Kim; Dayoon Kim; Seongkeun Jeong; Jin-Wook Yoo; Yunjin Jung
Journal:  Drug Des Devel Ther       Date:  2018-12-28       Impact factor: 4.162

10.  Perphenazine Attenuates the Pro-Inflammatory Responses in Mouse Models of Th2-Type Allergic Dermatitis.

Authors:  Min-Jeong Heo; Soo Young Choi; Chanmi Lee; Yeong Min Choi; In-Sook An; Seunghee Bae; Sungkwan An; Jin Hyuk Jung
Journal:  Int J Mol Sci       Date:  2020-05-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.